22 results
8-K
EX-1.1
NBSE
NeuBase Therapeutics Inc
6 Feb 15
Ohr Pharmaceutical Prices $25,000,000 Public Offering of Common Stock
12:00am
.
(c)General Disclosure Package. As of the Applicable Time (as defined below) and as of the Closing Date or the Option Closing Date (as defined below … Package”), (ii) the bona fide electronic roadshow (as defined in Rule 433(h)(5) of the Rules and Regulations) nor (iii) any individual Limited Use Free
8-K
EX-1.1
NBSE
NeuBase Therapeutics Inc
29 Apr 20
NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock
12:00am
Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus … . As of the Applicable Time, none of (A) the General Disclosure Package, (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together
8-K
EX-1.1
NBSE
NeuBase Therapeutics Inc
22 Apr 21
NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock
9:33am
Disclosure Package” means any Issuer General Use Free Writing Prospectuses issued at or prior to the Applicable Time, the most recent preliminary prospectus … not misleading. As of the Applicable Time, none of (A) the General Disclosure Package, (B) any individual Issuer Limited Use Free Writing Prospectus, when
8-K
EX-10.2
NBSE
NeuBase Therapeutics Inc
12 Jul 19
NeuBase Therapeutics Closes Merger Transaction with Ohr Pharmaceutical
5:23pm
) “Controlling Person” has the meaning set forth inSection 2.6(a).
(i) “Disclosure Package” has the meaning set forth inSection 2.6(a).
(j) “Exchange Act … the meaning set forth inSection 2.1(a).
(ee) “Shelf Takedown” has the meaning set forth inSection 2.1(e).
(ff) “Updated Disclosure Package” has
8-K
EX-10.41
NBSE
NeuBase Therapeutics Inc
8 Apr 14
Ohr Pharmaceutical Announces $18 Million Registered Direct Offering of Common Stock
12:00am
Statement, and the documents incorporated by reference therein (collectively, the “Disclosure Package”), prior to or in connection with the execution … . The Purchaser acknowledges that it has had the opportunity to review this Agreement and the Disclosure Package and has been afforded (i) the opportunity to ask
DEFA14A
syt1i0 40bi5g
11 Aug 23
Additional proxy soliciting materials
6:18am
DEFA14A
9jk5cdyu
1 Jul 20
Additional proxy soliciting materials
5:12pm
DEFA14A
o6v84z52o02mjss0o
22 Jul 22
Additional proxy soliciting materials
4:36pm
DEFA14A
jkm5kfsgrapqy oe
2 Jul 21
Additional proxy soliciting materials
7:06am
425
cwfl24 p7fc67c3rop8
8 Jul 19
Business combination disclosure
5:25pm
8-K
EX-99.1
kil93
12 May 22
NeuBase Therapeutics Reports Business Update and Financial Results
5:01pm
10QSB
ibqk55niusegchzgw4n
14 Nov 06
Quarterly report (small business)
12:00am
10QSB/A
eocwjikuu1kq a6wp
16 Nov 06
Quarterly report (small business) (amended)
12:00am
10QSB
v9rjtp6jwnj0xanmm pc
14 Aug 06
Quarterly report (small business)
12:00am
8-K
g6fa 5x1j7v2qqrgx1za
2 May 06
Other Events
12:00am
SB-2/A
lecr3717
17 Apr 03
Registration of securities for small business issuer (amended)
12:00am
SB-2/A
x6chf9rit8oa1pj
26 Jul 02
Registration of securities for small business issuer (amended)
12:00am
SB-2/A
gql ucvarc
30 Jan 03
Registration of securities for small business issuer (amended)
12:00am
SB-2/A
rfkdfuaj
5 Mar 03
Registration of securities for small business issuer (amended)
12:00am
SB-2/A
EX-99
qvqe iv09v
30 Jan 03
Registration of securities for small business issuer (amended)
12:00am